Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Chronic renal failure (CKD) is a risk factor for cardiovascular diseases such as heart attacks, strokes or heart failure. Brigham the scientist...
Read Full NewsPhase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.
Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
1.
Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.
2.
According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.
3.
When Healthcare Chatbots Fall Short of Human Connection
4.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
5.
Recently released national data on drug use and abuse among Americans.
1.
Understanding Bone Metastases: How Long Can Someone Live When Cancer Spreads To The Bones?
2.
The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment
3.
Lymphomatoid Papulosis: What You Need to Know
4.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
5.
Bone Marrow Immune Niche Remodeling in Hematopoiesis
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
Breast Cancer Awareness and Early Detection
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
4.
Common side effects of cancer treatment and how they are managed
5.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge